Bio-Techne Corp (FRA:TE1)
€ 76.5 1 (1.32%) Market Cap: 11.96 Bil Enterprise Value: 12.28 Bil PE Ratio: 65.48 PB Ratio: 6.45 GF Score: 92/100

Bio-Techne Corp at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2021 / 04:20PM GMT
Release Date Price: €108 (+0.93%)
Jialin Jin;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. We'll get started. Hello, everyone. My name is Jay Jin, and I'm part of the health care technology and distribution team here at Credit Suisse. Thanks, everyone, for joining us today.

Next up, we have Jim Hippel, Chief Financial Officer from Bio-Techne for a presentation. By way of background, Bio-Techne engages in development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets.

I will now hand it over to Jim for the presentation. But if anyone from the audience wants to ask any questions, please e-mail them to me at [email protected]. With that, Jim, over to you.

James T. Hippel
Bio-Techne Corporation - Executive VP of Finance & CFO

Great, Jay. Thank you very much. It's great to be here. Welcome, everyone. When I give an overview of our company, it's going to be geared probably a little more towards those of you who may not be as aware of our company and what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot